New hope for thalassemia patients: drug may cut blood transfusions

NCT ID NCT07215975

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. Researchers will follow 200 participants in the Middle East to track real-world results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia beta-thalassemia major thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THALASSEMIA

Contacts and locations

Locations

Prince Muhammad bin Nasser Hospital
NOT_YET_RECRUITING

Jizan, Saudi Arabia
Sultan Qaboos University Hospital
RECRUITING

Seeb, Muḩāfaz̧at Masqaţ, 123, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.